{"id":"W3015552022","doi":"10.1016/j.annonc.2020.03.299","title":"JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; Shionogi; Sanofi K.K.; Pharmacyclics; Sierra Oncology; Eli Lilly Japan; Abbott Japan; Novartis Pharma; AstraZeneca; Genentech; Celgene; Yakult Honsha; Otsuka Pharmaceutical; Daiichi Sankyo Europe; European Society for Medical Oncology; Pfizer Japan; Meiji Seika Pharma; Daiichi-Sankyo; Seagen; Revolution Medicines; Japan Society of Clinical Oncology; Jiangsu Hengrui Medicine; BeiGene; Astellas Pharma; Eisai; FibroGen; Japan Blood Products Organization; Eli Lilly and Company; EA Pharma Co., Ltd.; Les Laboratories Pierre Fabre; Ipsen; Array BioPharma; MSD K.K.; F. Hoffmann-La Roche; Boehringer Ingelheim Japan; Halozyme; Servier; Gilead Sciences; GlaxoSmithKline; Foundation Medicine; Kowa Company; Sanofi; Medtronic Japan; Amgen; Chugai Pharmaceutical; Symphogen; Pfizer; Biogen","keywords":"Medicine; Pembrolizumab; Microsatellite instability; Oncology; Clinical trial; Companion diagnostic; Internal medicine; Clinical Oncology; Cancer; Trk receptor; Immunotherapy; Receptor; Neurotrophin; Gene; Microsatellite","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001512668,0.0002354427,0.0006053745,0.0001266668,0.00006229006,0.000008656052,0.0001642166,0.0001293021,0.0003649071],"category_scores_gemma":[0.000702015,0.0001676597,0.00008095304,0.0002652753,0.0002674943,0.00005104739,0.00007123392,0.0001864332,0.000005812598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002035854,"about_ca_system_score_gemma":0.0007623199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001176258,"about_ca_topic_score_gemma":0.0003985876,"domain_scores_codex":[0.9983073,0.0001115887,0.0005478383,0.0004454033,0.0002377582,0.0003500595],"domain_scores_gemma":[0.9980119,0.0007013947,0.0002778982,0.0002178149,0.000579731,0.0002112155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04162991,0.005059768,0.8994547,0.00013646,0.000776527,0.00007056162,0.005163276,0.000129205,0.004059405,0.00003705254,0.01804908,0.02543412],"study_design_scores_gemma":[0.02419992,0.04941545,0.8273874,0.0004787638,0.0002812082,0.00003026636,0.001405243,0.0001913214,0.02736006,0.0001147705,0.06860451,0.0005310986],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648625,0.00010331,0.0000484327,0.03205258,0.0002804736,0.00156184,0.0003439752,0.00002729932,0.000719592],"genre_scores_gemma":[0.9881386,0.0002465805,0.007130632,0.003746036,0.00007198955,0.0002439334,0.0003145784,0.00003364313,0.00007397915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07206725,"threshold_uncertainty_score":0.6836963,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1042766919116311,"score_gpt":0.3936264719376828,"score_spread":0.2893497800260517,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}